Regulation of tumor promotion by RasGRP1

RasGRP1 对肿瘤促进的调节

• 批准号: 8497786
• 负责人: PATRICIA S LORENZO
• 金额: $ 3.27万
• 依托单位: UNIVERSITY OF HAWAII AT MANOA
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-09-02 至 2016-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8497786
• 关键词: 1,2-diacylglycerol; 3-Dimensional; Affinity; Biochemical; Biology; Carcinogens; Cells; Chemoprevention; Diglycerides; Engineering; Epidermal Growth Factor Receptor; Epidermis; Family; Goals; Grant; Growth Factor; Guanine Nucleotide Exchange Factors; Guanosine Triphosphate; Homeostasis; Human; Induced Mutation; Inflammation; Intervention; Lead; Ligands; Link; Malignant - descriptor; Malignant Neoplasms; Mediating; Modeling; Molecular Target; Mus; Mutate; Mutation; Nature; Oncogenes; Oncogenic; Pathway interactions; Phorbol Esters; Play; Predisposition; Protein Isoforms; Protein Kinase C; Proto-Oncogenes; Ras Signaling Pathway; Regulation; Role; Signal Pathway; Skin; Skin Cancer; Skin Carcinogenesis; Skin Carcinoma; Skin Neoplasms; Staging; System; Tetradecanoylphorbol Acetate; Therapeutic; Therapeutic Intervention; Transgenic Mice; Tumor Promoters; Tumor Promotion; Tumor Suppressor Genes; cancer therapy; carcinogenesis; cytokine; dosage; human disease; in vitro Model; keratinocyte; mimetics; mouse model; novel; overexpression; phorbol ester receptor; receptor; response; skin squamous cell carcinoma; therapeutic target; tumor; tumor initiation; tumor progression; tumorigenesis; tumorigenic

DESCRIPTION (provided by applicant): The mouse model of skin carcinogenesis has served to investigate the multistage nature of tumorigenesis and to identify novel oncogenes and tumor suppressor genes, as well as signaling pathways relevant in cancer. In the classic two-stage carcinogenesis model, Ras is activated by mutations induced by a carcinogen, and subsequent treatment with phorbol esters induces tumor promotion. However, the mechanisms that lead to tumor formation of cells initiated by Ras -and the participation of phorbol ester signaling pathways- are still poorly understood. Using the mouse skin model, we have identified RasGRP1 as a novel regulator of skin carcinogenesis. RasGRP1 links phorbol esters and Ras, since it is both, a high affinity phorbol ester receptor and a Ras activator. Using genetically modified mice we have shown that RasGRP1 participates in tumor initiation and progression in the two-stage carcinogenesis model through the biochemical activation of wild type Ras. Additionally, transgenic mice overexpressing RasGRP1 in the epidermis are prone to develop skin tumors spontaneously. Taken together, we hypothesize that RasGRP1 participates in carcinogenesis by mediating biochemical Ras activation and cooperating with oncogenic Ras in tumor formation. In this application, we propose to identify the mechanisms of cooperation between Ras and RasGRP1 during skin carcinogenesis, both in the absence and presence of Ras oncogenic mutations. In addition, we plan to extend our observation in mouse models to a human model using the 3-D organotypic culture of human skin. The specific aims are: (1) Determine the mechanism of tumorigenesis induced by RasGRP1 in the absence of Ras oncogenic mutations: following findings from our recent studies on wounding-induced tumors in the RasGRP1 transgenic mice, we will focus on the potential role of cytokines and EGFR ligands in activation of the RasGRP1-Ras axis in the skin; (2) Investigate the cooperation between RasGRP1 and oncogenic Ras in tumor progression in the skin: our hypothesis is that RasGRP1 activates wild type Ras isoforms, particularly N-Ras, and cooperates with oncogenic Ras in tumor progression; and (3) Elucidate the role of RasGRP1 in human keratinocyte homeostasis and transformation: we will use human in vitro models to validate and understand the functions of RasGRP1 in carcinogenesis. The significance of the studies is that the identification of RasGRP1 as a relevant target in Ras modulation in carcinogenesis can be used to develop new interventions for chemoprevention and/or cancer therapy. Moreover, the findings derived from this proposal should also contribute to advance our understanding of Ras signaling pathways beyond skin carcinogenesis, and may have applications to other systems where RasGRP1 is also expressed.

描述（由申请人提供）：皮肤癌发生的小鼠模型用于研究肿瘤发生的多阶段性质，并鉴定新的癌基因和肿瘤抑制基因，以及与癌症相关的信号通路。在经典的两阶段致癌模型中，Ras被致癌物诱导的突变激活，随后用佛波醇酯治疗诱导肿瘤促进。然而，由Ras引发的导致细胞肿瘤形成的机制以及佛波酯信号通路的参与仍然知之甚少。使用小鼠皮肤模型，我们已经确定RasGRP 1作为一种新的皮肤癌发生的调节剂。RasGRP 1连接佛波酯和Ras，因为它既是高亲和力佛波酯受体又是Ras激活剂。使用转基因小鼠，我们已经表明，RasGRP 1通过野生型Ras的生化激活参与肿瘤的发生和发展的两阶段致癌模型。此外，在表皮中过表达RasGRP 1的转基因小鼠易于自发地发展皮肤肿瘤。综上所述，我们推测RasGRP 1通过介导生化Ras激活并与致癌Ras合作参与肿瘤形成。在这个应用中，我们建议确定Ras和RasGRP 1在皮肤癌发生过程中的合作机制，无论是在Ras致癌突变的存在和不存在。此外，我们计划将我们在小鼠模型中的观察扩展到使用人类皮肤的3-D器官型培养的人类模型。具体目标是：（1）确定在没有Ras致癌突变的情况下由RasGRP 1诱导的肿瘤发生的机制：根据我们最近在RasGRP 1转基因小鼠中对创伤诱导的肿瘤的研究结果，我们将关注细胞因子和EGFR配体在皮肤中RasGRP 1-Ras轴激活中的潜在作用;（2）研究RasGRP 1和致癌Ras在皮肤肿瘤进展中的协同作用：我们的假设是RasGRP 1激活野生型Ras亚型，特别是N-Ras，并在肿瘤进展中与致癌Ras合作;（3）阐明RasGRP 1在人类角质形成细胞稳态和转化中的作用：我们将使用人类体外模型来验证和理解RasGRP 1在癌发生中的功能。这些研究的意义在于，RasGRP 1作为Ras调节致癌作用的相关靶标的鉴定可用于开发化学预防和/或癌症治疗的新干预措施。此外，从这一建议中得出的发现也有助于推进我们对皮肤癌发生以外的Ras信号通路的理解，并可能应用于RasGRP 1也表达的其他系统。